Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria S Asdourian

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral SurgeryMaria S Asdourian, Meyha N Swaroop, Hoda E Sayegh, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitorsMichael S Chang, Ted V Jacoby, Tracey S Otto, et al.
The British Journal of Dermatology|March 15, 2022
Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapyTed V Jacoby, Tracey S Otto, Maria S Asdourian, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|June 23, 2022
Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockadeMaria S Asdourian, Nishi Shah, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|February 10, 2024
Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort studyRachel M Reardon, Katherine L Perlman, Maria S Asdourian, et al.
Journal of the American Academy of Dermatology|June 20, 2022
Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective studyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|September 16, 2022
Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibitionTed V Jacoby, Nishi Shah, Maria S Asdourian, et al.
Journal of the American Academy of Dermatology|February 22, 2023
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanomaMichael R Stephens, Maria S Asdourian, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral SurgeryMaria S Asdourian, Meyha N Swaroop, Hoda E Sayegh, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2022
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitorsMichael S Chang, Ted V Jacoby, Tracey S Otto, et al.
The British Journal of Dermatology|March 15, 2022
Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapyTed V Jacoby, Tracey S Otto, Maria S Asdourian, et al.
Journal of the American Academy of Dermatology|February 3, 2023
Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|June 23, 2022
Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockadeMaria S Asdourian, Nishi Shah, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|February 10, 2024
Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort studyRachel M Reardon, Katherine L Perlman, Maria S Asdourian, et al.
Journal of the American Academy of Dermatology|June 20, 2022
Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective studyMaria S Asdourian, Ted V Jacoby, Nishi Shah, et al.
Journal of the American Academy of Dermatology|September 16, 2022
Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibitionTed V Jacoby, Nishi Shah, Maria S Asdourian, et al.
Journal of the American Academy of Dermatology|February 22, 2023
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanomaMichael R Stephens, Maria S Asdourian, Ted V Jacoby, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
Pageof 3